Matthew Szapacs, Ph.D. is a Group Leader and GSK Fellow in the Exploratory Biomarker Assay Group at GlaxoSmithKline. In this role Dr. Matthew Szapacs leads a group of scientists who focus on developing and validating bioanalytical methods for biomarkers using LC-MS/MS, immunoassay and cell based techniques. Prior to this, he has worked and led teams to develop quantitative methods using multiple bioanalytical platforms and last served as the US head of technology for the Bioanalytical Sciences and Toxicokinetics group. During his tenure at GSK, Dr. Szapacs has published and presented more than 30 times on the use of bioanalytical techniques in a regulated environment.
Back to panel discussion.